Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Pfizer, NYSE:PFE, has entered a global licensing agreement ...

A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. Pfizer made ...

Pfizer (PFE) shares fell in the premarket on Tuesday after the company reaffirmed its full-year outlook, indicating a revenue contraction for 2026 amid a nearly $1.5B impact attributed to some of its ...

Pfizer (PFE) announced on Tuesday that a mid-stage trial evaluating a monthly maintenance dosing regimen of its experimental obesity drug indicated that the GLP-1 receptor agonist PF’3944 (MET-097i) ...

That's the good news. The bad news is that while Pfizer "beat" on both sales and adjusted earnings, its earnings as calculated according to generally accepted accounting principles (GAAP) showed a ...

Pfizer is one of the world's largest pharmaceutical companies. It has a long history of navigating the competitive and technically complex industry. Pfizer's stock has lost half its value since late ...

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. An experimental obesity shot Pfizer got through a ...

From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or ...

Pfizer (NYSE:PFE) will release its quarterly earnings report on Tuesday, 2026-02-03. Here's a brief overview for investors ahead of the announcement. Analysts anticipate Pfizer to report an earnings ...

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Want to stay on top of ...